Invasive Candidiasis (IC)

IC includes

- Candidemia (bloodstream infections)
- Deep-seated candidiasis (affecting eyes, heart, brain, GI, etc.)

Epidemiology

- 2nd most common bloodstream infection
- 15%-40% mortality rate
- $40,000 average cost per episode

Resistance is a serious threat!

- 7% of IC isolates are resistant to an antifungal

*Species distribution varies by geographic region and patient population.

About the Impact of Deep-seated candidiasis

Echinocandin-resistant C. glabrata

Fluconazole-resistant C. parapsilosis

Multidrug-resistant C. auris

Non-albicans species on the rise (more resistant)

1. Gonzelez-Lara MF, Ostrosky-Zeichner L. Semin Respir Crit Care Med. 2020;41:3-12.

This educational initiative was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC-RFA-CK20-2003) to the University of Alabama at Birmingham. The University of Alabama at Birmingham is collaborating with the Mycoses Study Group Education & Research Consortium and Terranova Medica, LLC, on this initiative. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.